Syros Pharmaceuticals (SYRS) Tops Q3 EPS by 67c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($3.21), $0.67 better than the analyst estimate of ($3.88). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $5.18 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Nike names former Pfizer CFO David Denton as new finance chief
• SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters